Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to the U.S. ban on manufacturing mass copies of Wegovy, Amina Niasse of Reuters reports. These changes are focused on sharpening how we execute, without affecting our priorities or the specialties we’re committed to,” a company spokesperson said regarding the layoffs, according to Reuters.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- LifeMD price target raised to $15 from $12 at BTIG
- Mixed options sentiment in Hims and Hers Health with shares up 2.0%
- Why Hims & Hers Health Stock (HIMS) Is Too Hot to Handle
- ‘Time to Choose Sides on HIMS Stock’ as Analysts Assign Mixed Ratings
- Hims & Hers introduces 6-month Wegovy new customer offer